Subtopic Deep Dive
Pim Kinases in Cancer Metastasis
Research Guide
What is Pim Kinases in Cancer Metastasis?
Pim kinases are serine/threonine kinases that promote cancer metastasis by phosphorylating proteins involved in tumor cell migration, invasion, and epithelial-mesenchymal transition.
Pim kinases, including Pim-1, Pim-2, and Pim-3, activate downstream targets like metadherin to facilitate metastatic spread in cancers such as prostate and breast tumors. Research shows Pim kinases intersect with survival pathways like Akt and JAK/STAT signaling (Amaravadi, 2005; 401 citations). Over 10 key papers from 2005-2022 explore their therapeutic targeting, with foundational works exceeding 400 citations each.
Why It Matters
Pim kinases drive metastasis by enhancing cell motility and survival, making them targets for preventing cancer spread and improving survival in advanced tumors. Inhibitors blocking Pim-Akt crosstalk reduce invasion in preclinical models (Amaravadi, 2005). STAT3 pathway modulation, linked to Pim via JAK/STAT, suppresses metastasis in gliomas and other cancers (Kamran et al., 2013; Lo et al., 2008). Targeting these kinases informs combination therapies with PI3K or STAT3 inhibitors (Yang et al., 2019).
Key Research Challenges
Developing Selective Pim Inhibitors
Pim kinases share substrates with Akt, complicating selective inhibition without toxicity (Amaravadi, 2005). Clinical translation faces resistance mechanisms seen in related kinase pathways (Yang et al., 2022). Over 400-citation review highlights need for kinase-specific small molecules (Amaravadi, 2005).
Understanding Pim-STAT3 Crosstalk
Pim kinases activate STAT3 via JAK/STAT for metastasis, but exact phosphorylation sites remain unclear (Huang et al., 2022). STAT3 target genes drive invasion, requiring precise mapping (Carpenter and Lo, 2014). 628-citation paper details synthetic inhibitors for this pathway (Siveen et al., 2014).
Overcoming Metastasis Heterogeneity
Pim expression varies across tumor types, hindering universal therapies (Kamran et al., 2013). IL-6/JAK2/STAT3 signaling amplifies Pim effects differently in solid tumors (Huang et al., 2022). Translational advances demand patient-specific targeting strategies (Kamran et al., 2013).
Essential Papers
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma et al. · 2019 · Molecular Cancer · 1.5K citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · 2021 · Signal Transduction and Targeted Therapy · 1.5K citations
Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kin...
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Kodappully Sivaraman Siveen, Sakshi Sikka, Rohit Surana et al. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 628 citations
STAT3 Target Genes Relevant to Human Cancers
Richard L. Carpenter, Hui‐Wen Lo · 2014 · Cancers · 515 citations
Since its discovery, the STAT3 transcription factor has been extensively studied for its function as a transcriptional regulator and its role as a mediator of development, normal physiology, and pa...
The survival kinases Akt and Pim as potential pharmacological targets
Ravi K. Amaravadi · 2005 · Journal of Clinical Investigation · 401 citations
The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-depe...
Role of STAT3 in Cancer Metastasis and Translational Advances
Mohammad Zahid Kamran, Prachi Patil, Rajiv P. Gude · 2013 · BioMed Research International · 391 citations
Signal transducer and activator of transcription 3 (STAT3) is a latent cytoplasmic transcription factor, originally discovered as a transducer of signal from cell surface receptors to the nucleus. ...
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li · 2022 · Frontiers in Oncology · 380 citations
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation. It can activate janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathway. As ...
Reading Guide
Foundational Papers
Start with Amaravadi (2005; 401 citations) for Pim-Akt basics and survival roles; follow with Siveen et al. (2014; 628 citations) and Carpenter and Lo (2014; 515 citations) for STAT3 targeting linked to Pim pathways.
Recent Advances
Study Huang et al. (2022; 380 citations) for IL-6/JAK2/STAT3 in cancers and Yang et al. (2022; 232 citations) for kinase inhibitor resistance mechanisms relevant to Pim.
Core Methods
Core techniques include small molecule kinase inhibitors, STAT3 phosphorylation assays, and JAK/STAT pathway blockade; preclinical models test metastasis suppression (Zhong et al., 2021; Kamran et al., 2013).
How PapersFlow Helps You Research Pim Kinases in Cancer Metastasis
Discover & Search
Research Agent uses searchPapers and citationGraph to map Pim kinase literature from Amaravadi (2005; 401 citations), revealing connections to STAT3 and Akt pathways. exaSearch uncovers niche papers on Pim-metadherin interactions, while findSimilarPapers expands from Kamran et al. (2013) to 50+ related metastasis studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract Pim phosphorylation mechanisms from Amaravadi (2005), then verifyResponse with CoVe checks claims against Huang et al. (2022). runPythonAnalysis performs statistical verification of kinase expression data across papers using pandas, with GRADE grading for evidence strength in STAT3-Pim links.
Synthesize & Write
Synthesis Agent detects gaps in Pim inhibitor clinical data via contradiction flagging across Yang et al. (2019) and Zhong et al. (2021), generating exportMermaid diagrams of kinase networks. Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to produce a LaTeX review manuscript with synchronized references.
Use Cases
"Analyze Pim kinase expression correlations in metastasis datasets from provided papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/NumPy on extracted data from Amaravadi 2005 and Kamran 2013) → matplotlib plots of correlations output to researcher.
"Draft LaTeX review on Pim-STAT3 role in cancer invasion"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Siveen 2014, Carpenter 2014) + latexCompile → formatted PDF review with diagrams.
"Find code for Pim kinase signaling simulations from related papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for STAT3-Pim network models delivered to researcher.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ Pim kinase papers, chaining searchPapers → citationGraph → GRADE grading for a structured metastasis report. DeepScan applies 7-step analysis with CoVe checkpoints to verify Pim-Akt interactions from Amaravadi (2005). Theorizer generates hypotheses on Pim-STAT3 inhibitor combinations from Kamran et al. (2013) and Huang et al. (2022).
Frequently Asked Questions
What defines Pim kinases in cancer metastasis?
Pim kinases (Pim-1/2/3) are serine/threonine kinases that phosphorylate migration proteins, enabling tumor invasion and epithelial-mesenchymal transition (Amaravadi, 2005).
What methods target Pim kinases therapeutically?
Small molecule inhibitors block Pim-Akt and JAK/STAT pathways; synthetic STAT3 inhibitors show promise in preclinical metastasis models (Siveen et al., 2014; Zhong et al., 2021).
What are key papers on Pim kinases?
Amaravadi (2005; 401 citations) defines Pim as survival kinases; Kamran et al. (2013; 391 citations) details STAT3 metastasis role; Siveen et al. (2014; 628 citations) reviews inhibitors.
What open problems exist in Pim kinase research?
Selective inhibitors avoiding Akt crosstalk, precise Pim-STAT3 phosphorylation mapping, and tumor-specific expression heterogeneity remain unresolved (Yang et al., 2022; Huang et al., 2022).
Research Cancer Mechanisms and Therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pim Kinases in Cancer Metastasis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Mechanisms and Therapy Research Guide